Pharmacotherapy for acute respiratory infections caused by influenza viruses: Current possibilities

Routinely the influenza virus significantly contributes to the formation of the annual incidence of acute respiratory infections, with a peak in winter season. The high level of mutagenic potential of influenza viruses is a standard factor determining the complexity of the rational choice of pharmacotherapy. The upcoming epidemiological season 2020-2021 brings additional challenges for health care practitioners mediated by the widespread prevalence in the human population of a new infection caused by the SARS-CoV-2 virus affecting the respiratory system among many organs and systems. An adequate choice of pharmacotherapy tools should be based on high efficiency and safety of drugs, with a possible reduction in such negative factors as polypharmacy. This review includes comparative pharmacological characteristics of drugs with activity against RNA viruses, along with parameters of their clinical efficacy. © 2021 Consilium Medikum. All rights reserved.

Авторы
Zyryanov S.K. 1, 2 , Butranova O.I. 1 , Gaidai D.S.3 , Kryshen K.L.3
Номер выпуска
1
Язык
Русский
Страницы
114-124
Статус
Опубликовано
Том
93
Год
2021
Организации
  • 1 People's Friendship University of Russia, Moscow, Russian Federation
  • 2 City Clinical Hospital №24, Moscow, Russian Federation
  • 3 Saint Petersburg Institute of Pharmacy, Kuzmolovsky, Leningrad Region, Russian Federation
Ключевые слова
Baloxavir; COVID-19; Enisamium iodide; Favipiravir; Influenza virus; Ingavirin; Neuraminidase inhibitors; Umifenovir
Дата создания
20.04.2021
Дата изменения
20.04.2021
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/72268/
Поделиться

Другие записи

Merkin A.G., Akinfieva S.S., Martyushev-Poklad A.V., Beloskurskaya O.P., Dinov E.N., Ostrovsky S.L., Komarov A.N., Zakharova O.Yu., Kazhin V.A., Nikiforov I.A., Glover M.
Nevrologiya, Neiropsikhiatriya, Psikhosomatika. Ima-Press Publishing House. Том 13. 2021. С. 107-112